Open Access<p>Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma</p>
Author(s) -
Reinhard Walter,
Saskia Sydow,
Erika Gebel Berg,
Jens Kollmeier,
Daniel C. Christoph,
Sandra Christoph,
Wilfried Eberhardt,
Thomas Mairinger,
Jeremias Wohlschlaeger,
Kurt Werner Schmid,
Fabian Mairinger
Publication year - 2019
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s194337
Subject(s) - bortezomib , cisplatin , mesothelioma , proteasome inhibitor , cancer research , medicine , proteasome , apoptosis , oncology , pathology , chemotherapy , biology , multiple myeloma , biochemistry , microbiology and biotechnology
Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural mesothelioma (MPM) and failed to improve outcome. We present a potential explanation for this event.